High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. The JAK/STAT signaling pathway is involved in pancreatic cancer tumorigenesis. However, the prognostic value of JAK2 expression in resectable PDAC is unclear. METHOD: In this study, we performed a cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yang, Tang, Mei-Yue, Chen, Wei, Wang, Zhe, Wang, Si-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528024/
https://www.ncbi.nlm.nih.gov/pubmed/33029256
http://dx.doi.org/10.1155/2020/7656031
Descripción
Sumario:BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. The JAK/STAT signaling pathway is involved in pancreatic cancer tumorigenesis. However, the prognostic value of JAK2 expression in resectable PDAC is unclear. METHOD: In this study, we performed a clinicopathological analysis of 62 resectable PDAC cases with a primary focus on survival. JAK2 expression was examined by immunohistochemistry. The relationship between JAK2 expression and clinicopathological features and prognosis was analyzed. RESULTS: Survival curve analyses revealed that high levels of JAK2 expression predict a poor prognosis in resectable PDAC patients. Multivariate analysis confirmed that JAK2 expression can predict the prognosis of PDAC. CONCLUSIONS: Assessment of JAK2 protein expression may be a promising method to predict prognosis in patients with resectable PDAC.

Ejemplares similares